“…In addition to it is efficacy in the prevention of cardiovascular complications of diabetes by reducing platelet hyperactivity in patients with T2DM (Kudolo, Delaney, & Blodgett, 2005;Kudolo, Dorsey, & Blodgett, 2002;Lim et al, 2011), these findings trigger the investigations of GKB supplementation for T2DM patients (Aziz et al, 2018;Jie & Hai, 2005;Kudolo, 2001;Lasaite, Spadiene, Savickiene, Skesters, & Silova, 2014;Li, Zheng, Lou, Lu, & Ye, 2009;Shi et al, 2019;Zhao, Yu, Liu, & An, 2016). In a trial conducted on diabetic patients with uncontrolled glycemic status, GKB intake at a dosage of 120 mg/day for 3 months significantly reduced fasting blood sugar (FBS) and HbA1c levels (Aziz et al, 2018), and in another trial a significant decrease in total cholesterol, triglycerides, LDL-cholesterol levels was achieved after 1 month supplementation with 20 mg/day GKB in T2DM patients (Jie & Hai, 2005). However, in another study taking 72 mg/day GKB for 36 months did not affect lipidemic and glycemic parameters in diabetic patients (Zhao et al, 2016).…”